Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Advanced Enzyme Technologies Ltd

| Quarterly Financial Results Q3 FY 2025-26

BULLISH SENTIMENT

Report Source

⬤31st Jan 26

Summary : Advanced Enzyme Technologies reported strong Q3 and 9M FY26 results, approved a wind power plant investment, launched a new wellness subsidiary, and saw a favorable lawsuit outcome.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Consolidated Cost of materials consumed: Rs 456.40 million (Q3 FY26), Rs 1,383.51 million (9M FY26).
  2. Consolidated Employee benefits expense: Rs 412.62 million (Q3 FY26), Rs 1,203.48 million (9M FY26).
  3. Standalone Cost of materials consumed: Rs 373.63 million (Q3 FY26), Rs 1,375.86 million (9M FY26).
  4. Standalone Employee benefits expense: Rs 161.02 million (Q3 FY26), Rs 483.71 million (9M FY26).
  5. Consolidated Revenue from operations: Rs 1,719.49 million (Q3 FY26), Rs 5,423.90 million (9M FY26).
  6. Standalone Revenue from operations: Rs 955.84 million (Q3 FY26), Rs 3,363.56 million (9M FY26).
  7. Provision for a US lawsuit was reversed due to a favorable court order.
  8. Both standalone and consolidated unaudited financial results are presented and approved.

Corporate Overview

  1. India
  2. Netherlands
  3. Germany
  4. Assessing financial impact of new labor codes.
  5. Manufacturing and sales of enzymes.
  6. Formal and informative, announcing board meeting outcomes.
  7. Investment in a Group Captive Wind Power Plant SPV (up to 26% equity stake).
  8. Incorporation of Advanced Nutrazyme Private Limited for Nutrition and Wellness products.

Risk Factors

  1. New labor codes' financial impact uncertain.
  2. Reliance on other auditors for subsidiaries.
  3. Reliance on management for unaudited results.
  4. Potential for material misstatement in financials.

Key Drivers

  1. Approved strong Q3 and 9M financial results.
  2. Invested in new wind power plant SPV.
  3. Launched new subsidiary for wellness products.
  4. Won US lawsuit, provision reversed.

Auditor’s Report

  1. Unmodified conclusion on both consolidated and standalone unaudited financial results.
  2. Reliance on review reports of other auditors for four subsidiaries' interim financial results.
  3. Reliance on management-prepared unaudited interim financial results for four subsidiaries not reviewed by their auditors.
  4. Review of conversion adjustments for one overseas subsidiary's financial results.

Board Commentary

  1. Incremental financial impact from changes in labor codes, particularly gratuity and compensated absences.
  2. Government of India notified four new Labour Codes (Code on Wages, Industrial Relations Code, Social Security, Occupational Safety, Health and Working Conditions Code).
  3. Lawsuit in United States, with a favorable court order received.
  4. Investment in Group Captive Wind Power Plant SPV (up to 26% equity stake, cash consideration not exceeding ₹16.20 million).
  5. Investment of Rs 478.18 million in Advanced Enzymes Europe B.V. (AEEBV).
  6. Incorporation of Advanced Nutrazyme Private Limited (ANPL).

Corporate Governance

  1. Audit Committee and Board of Directors reviewed and approved financial results.
  2. Nomination and Remuneration Committee approved ESOP grants.

Management Discussion & Analysis

Future Strategy

  1. Investing in renewable energy for operational sustainability.
  2. Expanding product portfolio with Nutrition and Wellness range.

Operational Focus Areas

  1. Monitoring and ensuring compliance with new labor codes.

Risk Control Measures

  1. Monitoring finalization of Central/State Rules for labor codes.
  2. Lawsuit provision reversed due to favorable court order.

Critical Risks

  1. Uncertain financial impact from new labor codes.
Advanced Enzyme Technologies Ltd (ADVENZYMES) Quarterly Report Analysis & Insights | Dhanarthi